Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

BACKGROUND: Osteoprotegerin (OPG) is a tumour and/or bone derived factor that may protect tumour cells from apoptosis. In this study, we have measured serum OPG levels in untreated prostate cancer patients with advanced prostate cancer compared to patients with organ confined disease and in treated...

Detaylı Bibliyografya
Asıl Yazarlar:	Eaton, C, Wells, J, Holen, I, Croucher, P, Hamdy, F
Materyal Türü:	Journal article
Dil:	English
Baskı/Yayın Bilgisi:	2004

Benzer Materyaller

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
Yazar:: Eaton, C, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Role of osteoprotegerin (OPG) in cancer.
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

The role of osteoprotegerin in breast and prostate cancer
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

OPG is a survival factor for breast- and prostate cancer cells in vitro
Yazar:: Holen, I, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
Yazar:: Miles, L, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
Yazar:: Gamal B Mohamed, ve diğerleri
Baskı/Yayın Bilgisi: (2011-01-01)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
Yazar:: Holen Ingunn, ve diğerleri
Baskı/Yayın Bilgisi: (2009-07-01)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
Yazar:: Lili Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2016-11-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
Yazar:: Riham Eid, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
Yazar:: Indra Wijaya, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
Yazar:: Saba Tariq, ve diğerleri
Baskı/Yayın Bilgisi: (2022-02-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
Yazar:: Siamak Kazemi-Sufi, ve diğerleri
Baskı/Yayın Bilgisi: (2024-09-01)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
Yazar:: Shipman, C, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
Yazar:: Noura N. Alraouji, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
Yazar:: Chan Kai-Ming, ve diğerleri
Baskı/Yayın Bilgisi: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
Yazar:: Syed Muhammad Muneeb Akhtar, ve diğerleri
Baskı/Yayın Bilgisi: (2024-07-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
Yazar:: Waterman, E, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
Yazar:: Alice Wang, ve diğerleri
Baskı/Yayın Bilgisi: (2021-07-01)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
Yazar:: Cheema, Raheem Ramzan
Baskı/Yayın Bilgisi: (2021)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
Yazar:: Yao Jing, ve diğerleri
Baskı/Yayın Bilgisi: (2011-03-01)

Changes of serum osteoprotegerin level in recurrent urolithiasis
Yazar:: A. V. Savilov, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Can androgen receptor levels in the prostate predict non-organ-confined prostate cancer?
Yazar:: Hamdy, F
Baskı/Yayın Bilgisi: (2005)

Osteoprotegerin and the development of myeloma bone disease
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Dickkopf-1 levels and serum Osteoprotegerin in women with Osteoporosis
Yazar:: Mehrzad Hajialilo, ve diğerleri
Baskı/Yayın Bilgisi: (2013-12-01)

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations
Yazar:: Veselina Goranova-Marinova, ve diğerleri
Baskı/Yayın Bilgisi: (2007-07-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Yazar:: Martin Widschwendter, ve diğerleri
Baskı/Yayın Bilgisi: (2015-10-01)

Enhancing androgen ablation response in metastatic hormone-sensitive prostate cancer: the benefits of transurethral resection of the prostate
Yazar:: Yan Zhao, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Rapid Androgen-Responsive Proteome Is Involved in Prostate Cancer Progression
Yazar:: Jong-Kwang Kim, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

The influence of vitamin D administration on the clinical presentation, body mass index, and osteoprotegerin (OPG) level in a sample of Egyptian children with familial Mediterranean fever
Yazar:: Hanaa Reyad Abdallah, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
Yazar:: F. F. Rija, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
Yazar:: Yen-Liang Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2023-10-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Yazar:: Yosra Azizpour, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
Yazar:: Yosra Azizpour, ve diğerleri
Baskı/Yayın Bilgisi: (2020-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
Yazar:: Croucher, P, ve diğerleri
Baskı/Yayın Bilgisi: (2001)